Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17751908 | 1.00 | CASP2 (0.59) | CASP2FAAHL3MBTL1NAAADNM1 | |
| SCHEMBL24894495 | 0.98 | CASP2 (0.57) | CASP2FAAHL3MBTL1NAAADNM1 | |
| SCHEMBL7099277 | 0.92 | FAAH (0.56) | CASP2FAAHL3MBTL1NAAADNM1 | |
| SCHEMBL947922 | 0.90 | FAAH (0.53) | CASP2FAAHL3MBTL1NAAADNM1 | |
| SCHEMBL12160128 | 0.88 | TDP1 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL31248065 | 0.88 | TDP1 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL30020702 | 0.88 | TDP1 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL5267898 | 0.88 | TDP1 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL20542889 | 0.88 | TDP1 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL806270 | 0.87 | MEN1 (0.57) | CASP2FAAHL3MBTL1NAAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | CASP2 2358/4885FAAH 2296/4885L3MBTL1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.